Mantle Cell Lymphoma Excellence Forum

Mantle Cell Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Quiz

Pirtobrutinib for High-Risk Subtypes of Mantle Cell Lymphoma

09/19/2023

True or False: Results of the BRUIN trial indicated that after receiving pirtobrutinib, patients with MCL with classical histology had more efficacious outcomes than patients with MCL with blastoid or pleomorphic variants.

True or False: Results of the...

09/19/2023

Oncology

Videos

Promising Advances in the Treatment of Patients With Mantle Cell Lymphoma

09/13/2023

Michael Wang , MD;

At the 2023 Society of Hematologic Oncology Annual Meeting, Michael Wang, MD, reviews the latest research and treatment advances for patients with mantle cell lymphoma.

At the 2023 Society of...

09/13/2023

Oncology

Videos

Pirtobrutinib Demonstrates Durable Efficacy and Safety Among Patients With Covalent BTK Inhibitor Pretreated R/R MCL

09/05/2023

Kami J. Maddocks , MD;

Kami J. Maddocks, MD, analyzes the updated results of the BRUIN trial on the efficacy and safety of pirtobrutinib among patients with high-risk heavily pretreated R/R mantle cell lymphoma with prior covalent BTK inhibitor therapy.

Kami J. Maddocks, MD, analyzes...

09/05/2023

Oncology

Videos

Predicting Outcomes for Patients With Mantle Cell Lymphoma Using Integrative Prognostic Machine Learning Models

08/18/2023

Holly Hill , PhD;

Holly Hill, PhD, shares findings from a study on the value and clinical utility of integrative prognostic machine learning models as a tool for determining accurate predictions of outcomes among patients with MCL.

Holly Hill, PhD, shares findings...

08/18/2023

Oncology

Videos

Promising Prognostic Value of Diagnosis to Treatment Interval Among Patients With Newly Diagnosed Mantle Cell Lymphoma

08/17/2023

Narendranath Epperla , MD, MS;

Narendranath Epperla, MD, MS, shares findings assessing the potential significance of DTI for predicting outcomes for patients with newly diagnosed MCL.

Narendranath Epperla, MD, MS,...

08/17/2023

Oncology

Videos

BTK Inhibitors in Combination With Other Therapies as First-Line Treatment for Patients With Mantle Cell Lymphoma

06/27/2023

Vincent Ribrag , MD;

At the 2023 EHA Congress, Vincent Ribrag, MD, participated in a debate regarding if BTK inhibitors should be combined with other therapies such as bendamustine and rituximab as first-line treatment for mantle cell lymphoma.

At the 2023 EHA Congress,...

06/27/2023

Oncology

Videos

Acalabrutinib Combined With Bendamustine and Rituximab for Patients With Treatment-Naive or Relapsed/Refractory MCL

06/26/2023

Tycel Phillips ;

Tycel Phillips, MD, presented data at the 2023 ASCO annual meeting on the safety and efficacy of acalabrutinib in combination with bendamustine and rituximab among patients with treatment-naive or R/R mantle cell lymphoma.

Tycel Phillips, MD, presented...

06/26/2023

Oncology

Videos

Brexucabtagene Autoleucel Treatment for Patients With R/R Mantle Cell Lymphoma: Real-World Outcomes

06/21/2023

Swetha Kambhampati , MD;

At the 2023 ASCO annual meeting, Swetha Kambhampati, MD, provided insights into the real-world outcomes of brexucabtagene autoleucel therapy for patients with relapsed/refractory MCL through a subgroup analysis of outcomes by prior treatment.

At the 2023 ASCO annual meeting,...

06/21/2023

Oncology

Videos

Evaluating BCL6-Positive and CD10-Positive Expression for Mantle Cell Lymphoma Treatment and Management

06/14/2023

Won Jin Jeon , MD;

At the 2023 ASCO annual meeting, Won Jin Jeon, MD, presented data from a meta-analysis that explored the prognostic value of identifying BCL6 and CD10 variants in the treatment and management of mantle cell lymphoma.

At the 2023 ASCO annual meeting,...

06/14/2023

Oncology

Videos

Adding Ibrutinib to Induction or Maintenance With or Without AutoHSCT Shows Strong Efficacy, Acceptable Toxicity in MCL

12/21/2022

Martin Dreyling, MD, discusses data from the Triangle trial showing strong efficacy and acceptable safety with the addition of ibrutinib to induction or maintenance treatment with or without autoHSCT in younger patients with MCL.

Martin Dreyling, MD, discusses...

12/21/2022

Oncology

Recent News

Conference Insider

Dr Martin Discusses How to Approach MCL

03/23/2022

Emily Bader ;

Peter Martin, MD, discusses how to approach MCL, including what’s been learned so far and what’s to be expected, at the virtual Great Debates & Updates in Hematologic Malignancies.

Peter Martin, MD, discusses how...

03/23/2022

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology